Makeda Semret
- Jan 5, 2021
- 1 min read

Happy New year - and UPDATED COVID-19 treatment guidelines!

With the New Year, new guidelines! Our COVID-19 therapeutic working group has revised our COVID-19 management guidelines. Of note, empiric antibiotics are strongly DISCOURAGED for mild and moderate disease. Investigational or off-label therapies should NOT be given outside of clinical trials (several ongoing clinical trials at the MUHC); Criteria are proposed for potential identification of hyperimmune response, with recommendations to consult ID for severe cases.

Recent Posts

See All

Occupational exposure prophylaxy guidelines

ASP committee developed a post-exposure prophylaxis (HIV, hepB & hepC) guidelines in collaboration with the CVIS team. It is available on our website! Francois Bourdeau ASP MUHC coordinator

Update in COVID guidelines

The ASP committee updated the COVID guidelines. You will find the following change: -Removal of the pre-exposure prophylaxis guidelines since monoclonal antibodies are no longer easly available. -Clar

Correction in Antifungal prophylaxis for high-risk (immunocompromised)

Correction made for Heart transplant and Lung transplant recipients: both anti-mold AND anti-PJP prophylaxis recommended.